Sven Loffeler

Tonsberg, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis.

Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis.

Journal: Contemporary clinical trials
Published: March 22, 2026

Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).

Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).

Journal: BJU international
Published: March 12, 2024

DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.

DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.

Journal: British journal of cancer
Published: October 20, 2023

A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease.

A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease.

Journal: Scandinavian journal of urology
Published: July 11, 2022

Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.

Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.

Journal: BMJ open
Published: April 29, 2022

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance.

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance.

Journal: Scientific reports
Published: December 07, 2021

Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.

Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.

Journal: Prostate cancer and prostatic diseases
Published: June 03, 2020

Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly.

Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly.

Journal: Scandinavian journal of urology
Published: March 06, 2020

High Norwegian prostate cancer mortality: evidence of over-reporting.

High Norwegian prostate cancer mortality: evidence of over-reporting.

Journal: Scandinavian journal of urology
Published: January 13, 2018

Tumour heterogeneity poses a significant challenge to cancer biomarker research.

Tumour heterogeneity poses a significant challenge to cancer biomarker research.

Journal: British journal of cancer
Published: February 02, 2017

"Natural course" of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment.

"Natural course" of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment.

Journal: Scandinavian journal of urology
Published: July 04, 2015
Showing 1-11 of 11

Last Updated: 09/26/2026